Targeting kinases for the treatment of inflammatory diseases (Q38028572)

27 August 2017

Targeting kinases for the treatment of inflammatory diseases (English)

1 reference

27 August 2017

Susanne Müller

1

0 references

Stefan Knapp

object named as

Stefan Knapp

series ordinal

2

0 references

language of work or name

English

0 references

publication date

15 July 2010

1 reference

Expert Opinion on Drug Discovery

27 August 2017

1 reference

27 August 2017

5

1 reference

27 August 2017

9

1 reference

27 August 2017

867-881

1 reference

What have we learnt from targeted anti-TNF therapy?

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Monoclonal antibodies and progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Dissecting the role of mTOR: lessons from mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Growing roles for the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Suppression of B cell activation by cyclosporin A, FK506 and rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Sirolimus early graft nephrotoxicity: clinical and experimental data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

The TSC-mTOR signaling pathway regulates the innate inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Molecular phylogeny within type I cytokines and their cognate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

The molecular basis of X-linked severe combined immunodeficiency: the role of the interleukin-2 receptor gamma chain as a common gamma chain, gamma c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

The specificity of JAK3 kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Targeting mast cells in endometriosis with janus kinase 3 inhibitor, JANEX-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Primary immunodeficiency diseases due to defects in lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

A new modality for immunosuppression: targeting the JAK/STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Kinase inhibitors attract attention as oral rheumatoid arthritis drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Janus kinases in immune cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Therapeutic targeting of Janus kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Post-transcriptional gene regulation by MAP kinases via AU-rich elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

p38 MAP-kinases pathway regulation, function and role in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

TAB1beta (transforming growth factor-beta-activated protein kinase 1-binding protein 1beta ), a novel splicing variant of TAB1 that interacts with p38alpha but not TAK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

The autoimmune suppressor Gadd45alpha inhibits the T cell alternative p38 activation pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Targeting signal transduction as a strategy to treat inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Novel strategies for inhibition of the p38 MAPK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Targeting protein kinases for the development of anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Syk expression and novel function in a wide variety of tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

The FcepsilonRIbeta immunoreceptor tyrosine-based activation motif exerts inhibitory control on MAPK and IkappaB kinase phosphorylation and mast cell cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Tyrosine kinase inhibitors: a new approach for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Targeting Syk as a treatment for allergic and autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Therapeutic prospect of Syk inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

The IkappaB kinase - a bridge between inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Anti-inflammatory interventions of NF-kappaB signaling: potential applications and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Integrating cell-signalling pathways with NF-kappaB and IKK function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

NF-kappaB: linking inflammation and immunity to cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

The NF-kappaB-independent functions of IKK subunits in immunity and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

The IKK NF-kappa B system: a treasure trove for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Profound block in thymocyte development in mice lacking p56lck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Defective expression of p56lck in an infant with severe combined immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Defective p56Lck activity in T cells from an adult patient with idiopathic CD4+ lymphocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Discovery of 2-phenylamino-imidazo[4,5-h]isoquinolin-9-ones: a new class of inhibitors of lck kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: improvement of cell potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56(lck) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck -- a selectivity insight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Targeted therapy for systemic sclerosis: how close are we?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

The (un)targeted cancer kinome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

RETRACTED: GCK is essential to systemic inflammation and pattern recognition receptor signaling to JNK and p38

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Silencing mitogen-activated protein 4 kinase 4 (MAP4K4) protects beta cells from tumor necrosis factor-alpha-induced decrease of IRS-2 and inhibition of glucose-stimulated insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Induction of sustained expression of proto-oncogene c-fms by platelet-derived growth factor, epidermal growth factor, and basic fibroblast growth factor, and its suppression by interferon-gamma and macrophage colony-stimulating factor in human aorti

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

ZAK: a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

A role for DRAK2 in the germinal center reaction and the antibody response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Enhanced T cell apoptosis within Drak2-deficient mice promotes resistance to autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Drak2 regulates the survival of activated T cells and is required for organ-specific autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Tribbles: a family of kinase-like proteins with potent signalling regulatory function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Enhanced TLR-mediated NF-IL6 dependent gene expression by Trib1 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Regulation of expression and signalling modulator function of mammalian tribbles is cell-type specific

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Human tribbles homologue 2 is expressed in unstable regions of carotid plaques and regulates macrophage IL-10 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Mammalian Tribbles homolog 3 impairs insulin action in skeletal muscle: role in glucose-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

p38 pathway kinases as anti-inflammatory drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2010.504203

10.1517/17460441.2010.504203

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22823261